Fundz

Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform

PUBLIC · GLUESep 24, 2020

Amount Raised

$96 Million

Round Type

Series B

BostonBiotechnology

Description

Monte Rosa Therapeutics, a biotechnology company focused on developing precision medicines to degrade disease-causing proteins, announced today the closing of a Series B financing of $96 million. This financing will enable Monte Rosa to accelerate the growth of its pipeline, advance development candidates into the clinic and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach Monte Rosa Therapeutics will eradicate undruggable proteins that cause or drive the progression of genomically defined diseases intractable to standard care, including cancer.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Monte Rosa Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Viridian Therapeutics raised $91M on November 6, 2020.
  • Focal Medical raised $5.5M on November 6, 2020.
  • Memo Therapeutics AG raised an undisclosed amount (Series B) on November 6, 2020.
  • PaxMedica raised $3M (Seed) on November 6, 2020.
  • MediTrak Life Inc. raised $65K (Pre-Seed) on November 6, 2020.
  • Kytopen raised $3.1M (Seed) on November 6, 2020.

Who to call at Monte Rosa Therapeutics, Inc., and when

A new round usually means Monte Rosa Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Monte Rosa Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Monte Rosa Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Monte Rosa Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Monte Rosa Therapeutics, Inc.

Location

40 GUEST STREET

Boston, Massachusetts, United States

About

Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine based in the Technologiepark Basel. For more information, visit www.monterosatx.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Monte Rosa Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Monte Rosa Therapeutics, Inc.'s next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Monte Rosa Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.